Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 8-11

  Elmets, Craig A ^a   Athar, Mohammad ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; EFLORNITHINE; ENZYME; ORNITHINE DECARBOXYLASE; PLACEBO; POLYAMINE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BIOSYNTHESIS; CANCER PREVENTION; CLINICAL TRIAL; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SKIN CANCER; SMALL CELL CARCINOMA; ANIMAL; ENZYMOLOGY; METABOLISM; NOTE; SKIN TUMOR;

ANIMALS; CARCINOMA, BASAL CELL; HUMANS; ORNITHINE DECARBOXYLASE; SKIN NEOPLASMS;

EID: 77649208537     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0248     Document Type: Short Survey

References (39)

1. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55:490-500.
2. Athas WF, Hunt WC, Key CR. Changes in nonmelanoma skin cancer incidence between 1977-1978 and 1998-1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003;12:1105-8.
3. Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA, New Hampshire Skin Cancer Study Group. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. Int J Cancer 1999;81:555-9.
4. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294:681-90.
5. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermatol 2006;15:667-77.
6. Autier P, Boniol M, Severi G, Dore JF. Quantity of sunscreen used by European students. Br J Dermatol 2001;144:288-91.
7. Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol 2009;161:732-6.
8. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51.
9. Green A, Williams G, Neale R, et al. Daily sunscreen application and βcarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999;354:723-9.
10. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546-8.
11. van der Pols JC, Williams GM, Neale RE, Clavarino A, Green AC. Long-term increase in sunscreen use in an Australian community after a skin cancer prevention trial. Prev Med 2006;42:171-6.
12. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009;161 Suppl 3:78-84.
13. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
14. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-60.
15. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P, Xeroderma Pigmentosum Study Group. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Lancet 2001;357:926-9.
16. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994;330:1272-5.
17. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9.
18. Rundhaug JE, Fischer SM. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol 2008;84: 322-9.
19. Athar M, An KP, Morel KD, et al. Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem Biophys Res Commun 2001;280:1042-7.
20. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002;76:73-80.
21. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003;192:294-306.
22. +/- humans and mice. Cancer Prev Res 2010; 3:25-34.
23. Gilmour SK. Polyamines and nonmelanoma skin cancer. Toxicol Appl Pharmacol 2007;224:249-56.
24. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem 2006; 281:14529-32.
25. Zell JA, Ziogas A, Ignatenko N, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 2009;15:6208-16.
26. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res 2008;14:2303-9.
27. Tang X, Kim AL, Feith DJ, et al. Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice. J Clin Invest 2004;113:867-75.
28. Einspahr JG, Bowden GT, Alberts DS. Skin cancer chemoprevention: strategies to save our skin. Recent Results Cancer Res 2003;163: 151-64; discussion 264-6.
29. Evageliou NF, Hogarty MD. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin Cancer Res 2009;15: 5956-61.
30. Gensler HL. Prevention by α-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation. J Cancer Res Clin Oncol 1991;117:345-50.
31. Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, Mukhtar H. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol 2001;159:885-92.
32. Megosh LC, Hu J, George K, O'Brien TG. Genetic control of polyamine-dependent susceptibility to skin tumorigenesis. Genomics 2002;79:505-12.
33. Bailey HH, Kim K, Verma AK, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of α- difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 2010;3:35-47.
34. McLaren CE, Fujikawa-Brooks S, Chen WP, et al. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res 2008;1:514-21.
35. Wang X, Levic S, Gratton MA, Doyle KJ, Yamoah EN, Pegg AE. Spermine synthase deficiency leads to deafness and a profound sensitivity to α-difluoromethylornithine. J Biol Chem 2009;284:930-7.
36. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
37. Fischer SM, Lee M, Lubet RA. Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis 2001;22: 83-8.
38. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6.
39. Hickman JG, Huber F, Palmisano M. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin 2001;16:235-44.